7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $17M | -$21M | 60.4% | -114.1% | -$18M | $753000 | $2M |
| 2024 | $15M | -$11M | 60.0% | -74.3% | -$13M | — | $6M |
| 2023 | $14M | -$14M | 59.9% | -125.3% | -$13M | — | $2M |
| 2022 | $16M | -$24M | 62.5% | -156.2% | -$21M | — | $4M |
| 2021 | $17M | -$20M | 74.6% | -120.7% | -$18M | $1M | $24M |
| 2020 | $13M | -$12M | 79.7% | -92.1% | -$6M | $1M | $18M |
| 2019 | $11M | -$11M | 76.0% | -92.8% | -$6M | $4M | $469353 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $5M | -$8M | 59.5% | -128.7% | -$6M | $617000 | $2M |
| Dec '25 | $4M | -$7M | 78.1% | -166.9% | -$5M | $753000 | $2M |
| Sep '25 | $7M | -$5M | 58.0% | -69.8% | -$4M | $9M | $3M |
| Jun '25 | $4M | -$5M | 55.2% | -127.4% | -$4M | $8M | $4M |
| Mar '25 | $3M | -$4M | 50.0% | -129.9% | -$4M | — | $2M |
| Dec '24 | $4M | -$3M | 56.7% | -75.9% | -$3M | — | $6M |
| Sep '24 | $4M | -$3M | 60.5% | -68.5% | -$4M | — | $6M |
| Jun '24 | $4M | -$2M | 65.4% | -47.8% | -$3M | — | $7M |
| Mar '24 | $3M | -$4M | 56.7% | -110.7% | -$3M | — | $3M |
| Dec '23 | $3M | -$4M | 64.3% | -127.2% | -$3M | — | $2M |
| Sep '23 | $3M | -$2M | 52.9% | -110.3% | -$3M | — | $988000 |
| Jun '23 | $3M | -$6M | 61.8% | -133.0% | -$3M | — | $4M |
| Mar '23 | $4M | -$2M | 60.6% | -129.8% | -$4M | — | $7M |
| Dec '22 | $4M | -$6M | 60.4% | -153.5% | -$3M | — | $4M |
| Sep '22 | $4M | -$5M | 58.8% | -127.3% | -$6M | — | $7M |
| Jun '22 | $4M | -$7M | 61.9% | -166.4% | -$5M | — | $13M |
| Mar '22 | $4M | -$5M | 70.0% | -182.2% | -$6M | — | $18M |
| Dec '21 | $4M | -$7M | 70.7% | -168.7% | -$5M | $1M | $24M |
| Sep '21 | $5M | -$5M | 70.0% | -121.1% | -$4M | $1M | $29M |
| Jun '21 | $4M | -$4M | 80.6% | -90.3% | -$5M | $1M | $34M |
How the market has priced VVOS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Vivos Therapeutics, Inc.'s revenue has grown 5.9% per year. These are computed facts, not advice.
As of FY2025, Vivos Therapeutics, Inc. reported $753000 of total debt against $2M of cash; operating income covered interest expense -14.2×.
In FY2025, gross margin was 60.4%, operating margin -114.1%, and net margin -121.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.